Pazopanib

證據等級: L5

預測適應症: 10 個

Pazopanib: From Undocumented Original Indication to Renal Cell Carcinoma Associated with Xp11.2 Translocations/TFE3 Gene Fusions

One-Sentence Summary

Pazopanib's original approved indication is not recorded in the current evidence pack (no Taiwan/NZ license history on file). The TxGNN model predicts it may be effective for renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions, but this is currently supported by 0 clinical trials and 0 publications — the prediction stands entirely on the model score.

Quick Overview

Item	Content
Original Indication	Not documented (no licenses on file; `original_indications` field empty)
Predicted New Indication	Renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions
TxGNN Prediction Score	99.63%
Evidence Level	L5
New Zealand Market Status	Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (flagged as a High-severity data gap — DG002). However, the repurposing rationale attached to this prediction notes that pazopanib's known targets, VEGFR/PDGFR, are biologically relevant to this tumour type: TFE3 fusion-driven RCC commonly shows high VEGF expression, giving a plausible pathway-level rationale for anti-angiogenic activity.

That said, this link is described in the source rationale itself as theoretical only. There is no clinical trial or literature evidence — for this specific, rare RCC subtype — to substantiate the mechanistic hypothesis. The original indication being undocumented in this pack also means no direct disease-similarity comparison (e.g., to other RCC subtypes where pazopanib has established use) can be made from the available data.

Clinical Trial Evidence

Currently no related clinical trials registered

Literature Evidence

Currently no related literature available

New Zealand Market Information

Not marketed — 0 authorizations on file for pazopanib in the current dataset.

Cytotoxicity

Pazopanib is an antineoplastic agent (all predicted and referenced indications in this evidence pack are oncologic). Literature entries elsewhere in this pack consistently describe it as a multi-target tyrosine kinase inhibitor.

Item	Content
Cytotoxicity Classification	Targeted therapy (multi-target tyrosine kinase inhibitor; VEGFR/PDGFR pathway, per rationale and literature evidence in this pack)
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Please refer to the package insert warnings and precautions
Handling Protection	Please refer to the package insert warnings and precautions

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN score is high (99.63%), but this specific indication — an ultra-rare, molecularly defined RCC subtype — has zero clinical trials or literature support (Evidence Level L5: model prediction only). Blocking data gap DG001 (TFDA/NZ warnings and contraindications) also prevents even a preliminary safety assessment.

To proceed, the following is needed:

TFDA package insert warnings/contraindications (DG001, blocking)
Confirmed mechanism of action via DrugBank API (DG002)
Disease-specific clinical evidence (trials, case reports, or series) for Xp11.2 translocation/TFE3 fusion-associated RCC
Consider prioritizing other candidates in this same evidence pack with materially stronger support before advancing this one — notably liposarcoma (9 trials incl. multiple Phase 2, 20 publications) and dermatofibrosarcoma protuberans (4 trials incl. a dedicated Phase 2, 14 publications)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.